DrugPatentWatch Database Preview
Spil Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for SPIL, and when can generic versions of SPIL drugs launch?
SPIL has three approved drugs.
There are two US patents protecting SPIL drugs.
There are eight patent family members on SPIL drugs in seven countries and five supplementary protection certificates in two countries.
Summary for Spil
| International Patents: | 8 |
| US Patents: | 2 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-003 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | Start Trial | Y | Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-004 | Jan 26, 2018 | RX | Yes | Yes | 9,504,655 | Start Trial | Y | Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-002 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | Start Trial | Y | Start Trial | |||
| Spil | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210838-003 | Apr 16, 2019 | AB2 | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017523164 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016005934 | Start Trial |
| Brazil | 112017000468 | Start Trial |
| European Patent Office | 3166599 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0984957 | 2012/048 | Ireland | Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 1411900 | 2011/016 | Ireland | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 0984957 | SPC/GB11/013 | United Kingdom | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 1411900 | SPC/GB11/015 | United Kingdom | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
